P363: A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL

P363: A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL

Bibliographic Details
Main Authors:	Weiyang Liu, Yuanfang Liu, Yongmei Zhu, Xiangqin Weng, Cheng Wang, Wanyan Ouyang, Jie Xu, Jian‑qing MI, Jin Wang
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000968364.56569.fb

Similar Items

P370: EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULTS PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH T315I MUTATION AND RELAPSED/REFRACTORY DISEASE
by: Weiyang Liu, et al.
Published: (2023-08-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
by: Saskia Maletzke, et al.
Published: (2022-01-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
by: Saskia Maletzke, et al.
Published: (2022-01-01)

DASFAA 20202 Special Issue Editorial
by: Yingxia Shao, et al.
Published: (2020-10-01)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
by: Groffen John, et al.
Published: (2007-10-01)

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
by: Stephen E. Langabeer, et al.
Published: (2023-01-01)

Cup‐like blasts in an adult patient with BCR‐ABL1 positive B‐cell acute lymphoblastic leukemia
by: Zhenni Wang, et al.
Published: (2022-08-01)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
by: Mian Afsar, et al.
Published: (2012-09-01)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
by: Vicki Xie, et al.
Published: (2018-02-01)

Case report: BCR-ABL-positive acute lymphoblastic leukemia with bone destruction: a treatment dilemma
by: Shi Lijun, et al.
Published: (2024-02-01)

Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart
by: Hanna Kirchhoff, et al.
Published: (2022-02-01)

Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia
by: Rima Koka, et al.
Published: (2017-10-01)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity
by: Kathrin Rothfelder, et al.
Published: (2018-11-01)

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
by: Ya-nan Liu, et al.
Published: (2023-05-01)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
by: Dachuan Zeng, et al.
Published: (2022-05-01)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
by: Shohei Kawakami, et al.
Published: (2022-01-01)

BCR-ABL1-positive acute lymphoblastic leukemia following successful treatment of acute promyelocytic leukemia: case report
by: Shuang Fu, et al.
Published: (2023-06-01)

PB1749: APOPTOTIC EFFECT OF FLUMATINIB COMBINED WITH BCL2 INHIBITOR ON PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
by: Y. Gu, et al.
Published: (2022-06-01)

Basic and clinical study of efficacy and adverse effects of flumatinib in Ph+ ALL
by: Jun Wang, et al.
Published: (2023-05-01)

Amplification of the BCR: : ABL1 Fusion Gene: A Rare Phenomenon in B-cell Acute Lymphoblastic Leukemia
by: Debadrita Ray, et al.
Published: (2023-08-01)

No association between BCR-ABL1 fusion genes and clinical features of acute lymphoblastic leukaemia in Ghanaian patients
by: Victor Obeng Ofori, et al.
Published: (2020-10-01)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
by: Liuya Wei, et al.
Published: (2020-09-01)

An In-house Method for Molecular Monitoring of BCR-ABL
by: Hakkı Ogun Sercan, et al.
Published: (2012-12-01)

No Benefit of BCR-ABL1 Screening in Polycythemia
by: STEPHEN E. LANGABEER
Published: (2016-07-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Acute lymphoblastic leukemia with e1A3 BCR-ABL fusion protein: report of 2 cases and literature review
by: CHEN Siyu, et al.
Published: (2021-10-01)

P100: BCR/ABL1 p230 transcript in B-lymphoblastic leukemia/lymphoma: A case report
by: Agshin Taghiyev, et al.
Published: (2024-01-01)

In <i>BCR-ABL1</i> Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
by: Elisa Buzzatti, et al.
Published: (2022-03-01)

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
by: Ilana de França Azevedo, et al.
Published: (2014-10-01)

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
by: Berke, Z, et al.
Published: (2000)

Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190BCR-ABL
by: Run Qin, et al.
Published: (2023-01-01)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
by: Baum Karina J, et al.
Published: (2008-06-01)

BCR/ABL positive thrombocythemia: a diagnostic dilemma
by: Lubna Zafar, et al.
Published: (2017-01-01)

The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
by: Anahita Rafiei, et al.
Published: (2015-04-01)

Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]
by: Tara Ann Burns, et al.
Published: (2013-03-01)

PARP1 Characterization as a Potential Biomarker for <i>BCR::ABL1</i> p190+ Acute Lymphoblastic Leukemia
by: Caio Bezerra Machado, et al.
Published: (2023-11-01)

BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases
by: Anna Płotka, et al.
Published: (2023-07-01)

A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript
by: Aleksandra Mroczkowska, et al.
Published: (2022-02-01)

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
by: Xinhua Xiao, et al.
Published: (2020-06-01)

Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era
by: Ting Shi, et al.
Published: (2020-11-01)